周雨婷 朱斌 马雁

    摘 要 双特异性抗体现已成为肿瘤免疫治疗药物的热点，而其诱发的与免疫相关的细胞因子释放综合征(CRS)可能危及生命，已成为当前关注的焦点。我院Ⅰ期临床试验1例乳腺癌患者，首次输注重组人源化双功能单克隆抗体MBS301在11 min后出现胸闷、气急渐加重、周身湿冷、血氧下降等症状，考虑为CRS。予以甲泼尼龙琥珀酸钠抗炎，哌拉西林钠舒巴坦钠及利奈唑胺抗感染、化痰等对症治疗，患者症状好转。及时应用糖皮质激素可以治疗双特异性单克隆抗体引起的CRS。

    关键词 重组人源化双功能单克隆抗体 细胞因子释放综合征 糖皮质激素

    中图分类号：R979.19； R965.3 文献标志码：B 文章编号：1006-1533(2021)09-0036-03

    A case report of recombinant humanized bispecific monoclonal antibodyinduced cytokine release syndrome

    ZHOU Yuting*， ZHU Bin， MA Yan* *

    (Department of Pharmacy， Shanghai Cancer Center， Fudan University， Shanghai 200032， China)

    ABSTRACT The bispecific monoclonal antibody (mAbs) has been recently becoming a hotspot in cancer immunotherapy. Meanwhile， the immune-related fatal cytokine release syndrome (CRS) triggered by bispecific mAbs may be life-threatening and has become the focus of current attention. We reported a case that a female patient with relapse and metastatic breast cancer who underwent an initial infusion of MBS301 developed such symptoms as chest distress ......